SCHEMBL26640328

SCHEMBL26640328

CS(=O)(=O)Cc1ncc(Br)cc1Cl

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.38
MEN1 O00255 4/20 0.38
PLAU P00749 1/20 0.37
POLB P06746 1/20 0.36
ALDH1A1 P00352 5/20 0.34
NPSR1 Q6W5P4 3/20 0.34
HTT P42858 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
NPC1 O15118 1/20 0.33
LMNA P02545 2/20 0.33
MAPT P10636 2/20 0.33
KDM4E B2RXH2 2/20 0.33
HSD17B10 Q99714 1/20 0.33
NMT1 P30419 2/20 0.32
PKM P14618 1/20 0.32
APOBEC3G Q9HC16 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16722454 0.82 KMT2A (0.36) KMT2AMEN1PLAUPOLBALDH1A1
SCHEMBL26640061 0.81 KMT2A (0.38) KMT2AMEN1ALDH1A1NPSR1CA1
SCHEMBL30648618 0.81 KMT2A (0.38) KMT2AMEN1ALDH1A1NPSR1CA1
SCHEMBL25316528 0.79 CA1 (0.37) KMT2AMEN1ALDH1A1HTTCA1
SCHEMBL30507028 0.79 CA1 (0.37) KMT2AMEN1ALDH1A1HTTCA1
SCHEMBL16728654 0.79 PLAU (0.34) KMT2AMEN1PLAUPOLBALDH1A1
SCHEMBL856143 0.76 CA1 (0.40) KMT2AMEN1POLBALDH1A1NPSR1
SCHEMBL18179659 0.76 PLAU (0.42) KMT2AMEN1PLAUALDH1A1NPSR1
SCHEMBL29159933 0.74 PLAU (0.43) KMT2AMEN1PLAUALDH1A1HTT
SCHEMBL30648735 0.74 PLAU (0.43) KMT2AMEN1PLAUALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4522618-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS Merck Patent GmbH (DE) 2025-03-19 EP disclosed
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS MERCK HEALTHCARE KGAA (DE) 2024-01-25 US disclosed
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS MERCK HEALTHCARE KGAA (DE) 2024-01-25 US disclosed
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS MERCK HEALTHCARE KGAA (DE) 2024-01-25 US disclosed
WO-2023220541-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS MERCK PATENT GMBH (DE) 2023-11-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS PDXK, DTYMK, HIPK1 KMT2A 2685/4885MEN1 2978/4885PLAU 1587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.